92668-50-3

Basic information

• Product Name: Alanine, N-(((4-fluoro-3-(trifluoromethyl)phenyl)amino)carbonyl)-2-methyl-, methyl ester
• CAS NO: 92668-50-3
• Molecular Weight: 322.259
• Mol File: 92668-50-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Alanine, N-(((4-fluoro-3-(trifluoromethyl)phenyl)amino)carbonyl)-2-methyl-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Alanine, N-(((4-fluoro-3-(trifluoromethyl)phenyl)amino)carbonyl)-2-methyl-, methyl ester(92668-50-3)
• EPA Substance Registry System: Alanine, N-(((4-fluoro-3-(trifluoromethyl)phenyl)amino)carbonyl)-2-methyl-, methyl ester(92668-50-3)

Safety Data

• Hazardous Substances Data: 92668-50-3(Hazardous Substances Data)

Upstream product

• 15028-41-8 methyl 2-aminoisobutyrate hydrochloride 
• 54213-21-7 α-Isocyanatobuttersaeure-methylester 
• 2357-47-3 4-Fluoro-3-trifluoromethylaniline 

Downstream Products

• 1179804-28-4 4-{2-[3-(4-fluoro-3-trifluoromethylphenyl)-5,5-dimethyl-2,4-dioxoimidazolidin-1-ylmethyl]benzoyl}benzoic acid 
• 92668-58-1 5,5-Dimethyl-2,4-dioxo-3-(α,α,α,4-tetrafluor-m-tolyl)-1-imidazolidincarbonsaeureethylester 
• 92668-59-2 5,5-Dimethyl-1-nitro-3-(α,α,α,4-tetrafluor-m-tolyl)hydantoin 
• 92668-48-9 1-Chlor-5,5-dimethyl-3-(α,α,α,4-tetrafluor-m-tolyl)hydantoin 
• 70842-04-5 5,5-dimethyl-3-(α,α,α,4-tetrafluoro-m-tolyl)hydantoin 

Relevant articles and documents

Heterocycle-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising them and use thereof

The invention relates to compounds of formula (I) wherein the groups R and R′, A, D, E, G, L, p and R1 to R10 have the stated meanings and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs.

Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use

This invention relates to arylaminoaryl-alkyl-substituted imidazolidone-2,4-diones of formula (I) and also to their physiologically tolerated salts: Wherein R, R′, R1 to R10, A, D, E, G, L and p are as defined herein. The invention also relates to processes for preparing them, pharmaceutical compositions comprising them and their therapeutic use. The compounds are suitable, for example, as anti-obesity drugs and for treating cardiometabolic syndrome.